HomePLX • NYSEAMERICAN
add
Protalix Biotherapeutics Inc
Previous close
$1.17
Day range
$1.13 - $1.19
Year range
$1.09 - $3.55
Market cap
83.28M USD
Avg Volume
376.49K
P/E ratio
11.31
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 10.49M | 21.69% |
Operating expense | 7.24M | -16.87% |
Net income | -6.04M | -61.60% |
Net profit margin | -57.64 | -32.81% |
Earnings per share | — | — |
EBITDA | -5.30M | -138.83% |
Effective tax rate | 5.94% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 44.56M | 100.90% |
Total assets | 84.43M | 51.35% |
Total liabilities | 50.86M | -23.43% |
Total equity | 33.57M | — |
Shares outstanding | 73.05M | — |
Price to book | 2.53 | — |
Return on assets | -16.32% | — |
Return on capital | -22.62% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -6.04M | -61.60% |
Cash from operations | 3.60M | 237.69% |
Cash from investing | -342.00K | -106.90% |
Cash from financing | 0.00 | -100.00% |
Net change in cash | 3.23M | -49.52% |
Free cash flow | 5.76M | 637.67% |
About
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
CEO
Founded
1993
Headquarters
Website
Employees
208